MedTrace Logo

A Study to Evaluate the Safety, Immunogenicity, and Efficacy of UB-612 COVID-19 Vaccine

NCT04683224 · Status: WITHDRAWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL

Last updated 2022-04-04

No results posted yet for this study

Summary

This is a Phase 2/3, randomized, multicenter, double-blind, dose-response study to evaluate the safety, immunogenicity, and efficacy of UB 612 in 2 age groups, adults 18 to 59 and ≥60 years of age with or without comorbidities.

Conditions

Interventions

BIOLOGICAL

UB-612

100 µg \[microgram\] of an experimental study vaccine

OTHER

Placebo

Placebo is a 0.9% sodium chloride (normal saline) injection

Sponsors & Collaborators

  • Diagnósticos da América S/A (DASA)

    collaborator UNKNOWN

  • Vaxxinity, Inc.

    lead INDUSTRY

Principal Investigators

  • Gray Heppner · Chief Medical Officer

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-02-01
Primary Completion
2023-03-22
Completion
2023-03-22

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04683224 on ClinicalTrials.gov